Objective: To explore edaravone in treatment of acute cerebral infarction. Method: We randomly selected 60 patients with acute cerebral infarction, They were randomly divided into two groups. The control group received routine medical treatment, the experimental group received intravenous infusion of edaravone. Follow-up for 1 to 3 months and then used Chinese Stroke Scale ( CSS ) and activities of daily living ( ADL ) to evaluate the effect and statistics of its clinical efficacy and quality of life. Result: Experimental group having an effect in 22 cases, effective 6 cases, is not valid in 2 cases, total efficiency ( including having an effect and valid ) is 92. 8% , higher than the control group ( P <0. 05 ). Conclusion: Early therapeutic effect of edaravone on acute cerebral infarction patients is significant, safe and effective, It can enhance their daily life and improve the quality of life.%目的 探讨依达拉奉治疗急性脑梗塞的疗效,降低并发症的发生率.方法:抽取我院2009年1月至2011年1月收治的60例急性脑梗塞患者,随机分为两组.对照组30例,行常规内科治疗.实验组30例,在常规内科治疗的基础上加用依达拉奉静脉滴注.术后随访1-3个月,治疗后疗效对比评估采用中国卒中量表(CSS)和日常生活能力(ADL)两项进行评定,并对疗效结果进行统计.结果 两组患者相比,治疗前两项评分差异均无统计学意义(P>0.05),治疗后实验组CSS和ADL评分均优于对照组,差异有统计学意义(P<0.05).实验组术后显效22例,有效6例,无效2例,总有效率(包括显效和有效)为92.8%优于对照组,差异有统计学意义(P<0.05).结论:早期应用依达拉奉对急性脑梗塞患者疗效显著,有利于提高其日常生活能力,是一种安全有效的药物,值得在临床上推广使用.
展开▼
